# uncontrolled hypertension FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/uncontrolled-hypertension

> 4 upcoming FDA catalysts in uncontrolled hypertension: RTN-001 (RTSN) on March 2027 (primary completion); RTN-001 (RTSN) on Mar to Jun 2027 (topline data readout); Baxfendy (baxdrostat, AZN) on Feb to May 2028 (topline data readout); Baxfendy (baxdrostat, AZN) on February 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2025 | [Zilebesiran trial start](https://sec-api.dev/pdufa/zilebesiran) | ALNY | uncontrolled hypertension | completed | "In September 2025, we initiated a Phase 3 cardiovascular outcomes clinical trial, ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), which is designed to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension on two or more antihypertensives, one being a diuretic." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm)) |
| October 15, 2025 | [REGN5381 primary completion](https://sec-api.dev/pdufa/regn5381) | REGN | Uncontrolled Hypertension | withdrawn | "NCT06833190 (REGN5381 in Adult Participants With Uncontrolled Hypertension): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06833190)) |
| March 2027 | [RTN-001 primary completion](https://sec-api.dev/pdufa/rtn-001) | RTSN | Uncontrolled Hypertension | scheduled | "NCT07142356 (A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Retension Pharmaceuticals. Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07142356)) |
| Mar to Jun 2027 | [RTN-001 topline data readout](https://sec-api.dev/pdufa/rtn-001) | RTSN | Uncontrolled Hypertension | scheduled | "NCT07142356 (A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Retension Pharmaceuticals. Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07142356)) |
| Feb to May 2028 | [Baxfendy (baxdrostat) topline data readout](https://sec-api.dev/pdufa/baxdrostat) | AZN | Uncontrolled Hypertension | scheduled | "NCT07686120 (A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07686120)) |
| February 2028 | [Baxfendy (baxdrostat) primary completion](https://sec-api.dev/pdufa/baxdrostat) | AZN | Uncontrolled Hypertension | scheduled | "NCT07686120 (A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07686120)) |

## Drugs

- [Zilebesiran](https://sec-api.dev/pdufa/zilebesiran) (ALNY)
- [REGN5381](https://sec-api.dev/pdufa/regn5381) (REGN)
- [RTN-001](https://sec-api.dev/pdufa/rtn-001) (RTSN)
- [Baxfendy (baxdrostat)](https://sec-api.dev/pdufa/baxdrostat) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/uncontrolled-hypertension.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "uncontrolled hypertension FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/uncontrolled-hypertension

```bibtex
@misc{secapidev_indications_uncontrolled_hypertension_20261116,
  title        = {uncontrolled hypertension FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/uncontrolled-hypertension}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_uncontrolled_hypertension_20261116","title":"uncontrolled hypertension FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/uncontrolled-hypertension","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
